Clinic
Baptist Health
Baptist Health was paid $14.02M by Medicaid between Jan 2018 and Dec 2024, across 301 billing codes. Its largest line is 80047, — 7.1% of everything it billed.
33Billing provider infoBAPTIST HEALTH
NORTH LITTLE ROCK, AR 72117
NORTH LITTLE ROCK, AR 72117
33aNPI1497790042assigned 06/18/2006
33bProvider typeRehabilitation Clinic/Center
28Total paid$14.02M
24GClaims846,076
24DCodes billed301
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rehabilitation Clinic/Center providers in Arkansas
Rank by total paid#4 of 27
Median peer was paid$3.03M
This provider vs. median4.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WELLS, TROY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 123,855 | $1.47M | |
| 2019 | 137,523 | $1.99M | |
| 2020 | 113,014 | $1.75M | |
| 2021 | 122,251 | $2.17M | |
| 2022 | 129,700 | $2.47M | |
| 2023 | 133,328 | $2.56M | |
| 2024incomplete | 86,405 | $1.61M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80047 | 7.1% | 33,361 | 28,175 | $995K | |
| 70450 | Computed tomography, head or brain; without contrast material | 5.1% | 8,353 | 7,434 | $720K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 4.9% | 6,610 | 6,045 | $688K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.7% | 5,235 | 4,701 | $654K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 4.3% | 4,591 | 2,087 | $606K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 3.2% | 2,141 | 1,779 | $444K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 3.1% | 4,406 | 3,769 | $432K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 2.7% | 2,073 | 1,889 | $379K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.4% | 46,888 | 37,973 | $333K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.2% | 13,217 | 10,567 | $315K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 2.0% | 2,719 | 2,411 | $287K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.9% | 27,463 | 22,488 | $272K |
289 more codes
| 36415 | Collection of venous blood by venipuncture | 1.9% | 53,309 | $267K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.9% | 8,418 | $260K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.8% | 6,070 | $256K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.7% | 4,288 | $238K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.6% | 3,555 | $230K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.5% | 1,895 | $210K |
| 71046 | Radiologic examination, chest; 2 views | 1.5% | 14,285 | $209K |
| 93975 | 1.4% | 2,720 | $196K | |
| J2785 | Injection, regadenoson, 0.1 mg | 1.3% | 1,319 | $181K |
| 87631 | 1.2% | 2,158 | $162K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.1% | 1,981 | $157K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.1% | 1,632 | $156K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,031 | $137K |
| 80076 | <1% | 12,762 | $133K | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 11,436 | $128K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 592 | $122K |
| 84703 | <1% | 13,026 | $119K | |
| 80051 | <1% | 6,059 | $108K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,200 | $108K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 12,635 | $106K |
| 86901 | <1% | 4,793 | $104K | |
| 83880 | <1% | 4,786 | $104K | |
| 84484 | <1% | 14,292 | $100K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 367 | $100K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,714 | $94K |
| 72141 | <1% | 506 | $91K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 5,238 | $83K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 10,433 | $82K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,951 | $79K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 680 | $78K |
| 82550 | <1% | 13,889 | $73K | |
| 73560 | <1% | 2,488 | $69K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 337 | $69K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 925 | $62K |
| 97161 | <1% | 1,119 | $61K | |
| 82962 | <1% | 7,929 | $60K | |
| 83690 | <1% | 9,379 | $60K | |
| 70486 | <1% | 516 | $60K | |
| 84132 | <1% | 2,569 | $59K | |
| 71250 | <1% | 729 | $57K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,314 | $55K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,314 | $55K |
| 74022 | <1% | 2,867 | $55K | |
| 72100 | <1% | 2,281 | $53K | |
| 81001 | <1% | 16,968 | $51K | |
| 85027 | <1% | 7,697 | $51K | |
| 36430 | <1% | 636 | $51K | |
| 86900 | <1% | 4,794 | $49K | |
| 87070 | <1% | 1,915 | $48K | |
| 93971 | <1% | 1,292 | $47K | |
| 76801 | <1% | 1,398 | $47K | |
| 80306 | <1% | 3,025 | $47K | |
| 87040 | <1% | 4,135 | $46K | |
| 76000 | <1% | 972 | $46K | |
| 81025 | <1% | 5,479 | $46K | |
| 82947 | <1% | 10,206 | $45K | |
| 96376 | <1% | 4,827 | $44K | |
| 71045 | Radiologic examination, chest; single view | <1% | 6,397 | $43K |
| 83735 | <1% | 7,870 | $42K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,179 | $42K |
| 83605 | <1% | 4,522 | $42K | |
| 73630 | <1% | 1,607 | $41K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 9,075 | $41K |
| 82077 | <1% | 2,698 | $40K | |
| 73030 | <1% | 1,839 | $39K | |
| 84145 | <1% | 2,487 | $38K | |
| 82565 | <1% | 7,658 | $36K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,529 | $36K |
| 73130 | <1% | 1,426 | $34K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 9,122 | $34K |
| 85379 | <1% | 3,918 | $34K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 17,194 | $33K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,069 | $32K |
| 90715 | <1% | 1,831 | $30K | |
| 87088 | <1% | 4,236 | $30K | |
| 80053 | Comprehensive metabolic panel | <1% | 2,157 | $30K |
| 81003 | <1% | 14,972 | $30K | |
| 82803 | <1% | 1,894 | $30K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,226 | $29K |
| 80143 | <1% | 1,615 | $28K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,250 | $28K |
| 80179 | <1% | 1,593 | $28K | |
| 84702 | <1% | 2,843 | $28K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 140 | $27K |
| 85014 | <1% | 3,203 | $27K | |
| 72040 | <1% | 1,119 | $26K | |
| 82150 | <1% | 4,158 | $25K | |
| 80320 | <1% | 1,979 | $25K | |
| 73502 | <1% | 1,187 | $25K | |
| 87077 | <1% | 2,804 | $24K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,065 | $23K |
| 73610 | <1% | 1,236 | $23K | |
| 97165 | <1% | 449 | $23K | |
| 85610 | <1% | 6,632 | $23K | |
| 99283 | Emergency room visit (moderate) | <1% | 3,009 | $22K |
| 93017 | <1% | 1,731 | $21K | |
| 77066 | Tomosynthesis, mammo | <1% | 340 | $21K |
| 84520 | <1% | 6,230 | $20K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,983 | $20K |
| 82375 | <1% | 1,970 | $19K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 410 | $18K |
| 99284 | Emergency room visit (serious) | <1% | 4,744 | $18K |
| 74018 | <1% | 1,010 | $18K | |
| 76642 | <1% | 634 | $17K | |
| 85730 | <1% | 3,752 | $17K | |
| 93458 | <1% | 252 | $17K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 489 | $16K |
| 80050 | General health panel | <1% | 516 | $16K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,589 | $16K |
| 12001 | <1% | 85 | $16K | |
| 80061 | Lipid panel | <1% | 1,230 | $16K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,264 | $16K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,250 | $14K |
| 97162 | <1% | 279 | $14K | |
| 87486 | <1% | 340 | $14K | |
| 87581 | <1% | 339 | $14K | |
| 71020 | <1% | 1,158 | $14K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,781 | $13K |
| 86850 | <1% | 3,500 | $13K | |
| 97001 | <1% | 546 | $13K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 360 | $13K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 951 | $13K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,711 | $13K |
| 76830 | Ultrasound, transvaginal | <1% | 306 | $13K |
| 10060 | <1% | 70 | $13K | |
| 85018 | <1% | 3,274 | $13K | |
| 80329 | <1% | 1,022 | $13K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,906 | $13K |
| 87186 | <1% | 2,278 | $12K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,175 | $12K |
| 85055 | <1% | 791 | $12K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 314 | $10K |
| 87210 | <1% | 1,836 | $10K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 556 | $9K |
| 82010 | <1% | 1,333 | $9K | |
| 73110 | <1% | 446 | $9K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,945 | $9K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 198 | $8K |
| 70496 | <1% | 55 | $7K | |
| 70498 | <1% | 55 | $7K | |
| 76775 | <1% | 473 | $7K | |
| 82805 | <1% | 304 | $7K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 34 | $7K |
| 85007 | <1% | 2,421 | $7K | |
| 80069 | <1% | 907 | $7K | |
| 95811 | <1% | 75 | $6K | |
| 82247 | <1% | 834 | $6K | |
| 87205 | <1% | 2,065 | $6K | |
| 94760 | <1% | 444 | $6K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 468 | $5K |
| 86923 | <1% | 369 | $5K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 5,595 | $5K |
| 87075 | <1% | 1,062 | $5K | |
| 72131 | <1% | 60 | $5K | |
| A6213 | Foam dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., with any size adhesive border, each dressing | <1% | 642 | $5K |
| J1815 | Injection, insulin, per 5 units | <1% | 4,421 | $4K |
| 51701 | <1% | 66 | $4K | |
| C1769 | Guide wire | <1% | 145 | $4K |
| 76536 | <1% | 80 | $3K | |
| 0353U | <1% | 531 | $3K | |
| 93296 | <1% | 280 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 10,339 | $3K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,808 | $3K |
| 99285 | Emergency room visit (most serious) | <1% | 196 | $3K |
| 97597 | <1% | 167 | $3K | |
| 93880 | <1% | 113 | $3K | |
| 82607 | <1% | 320 | $3K | |
| 99152 | <1% | 1,317 | $3K | |
| 82746 | <1% | 238 | $2K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 325 | $2K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 43 | $2K |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 199 | $2K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 3,074 | $2K |
| 72070 | <1% | 155 | $2K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 137 | $2K |
| 73070 | <1% | 137 | $2K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 34 | $2K |
| 73590 | <1% | 93 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,116 | $2K |
| J2704 | Injection, propofol, 10 mg | <1% | 6,026 | $2K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,867 | $2K |
| 93976 | <1% | 45 | $2K | |
| 86140 | <1% | 363 | $2K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 67 | $2K |
| 77062 | <1% | 28 | $2K | |
| A9270 | Non-covered item or service | <1% | 14,044 | $2K |
| 71271 | <1% | 26 | $2K | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | <1% | 42 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,721 | $2K |
| 71010 | <1% | 260 | $1K | |
| 80349 | <1% | 86 | $1K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,940 | $1K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,337 | $1K |
| 82728 | <1% | 102 | $1K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 17 | $1K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,250 | $1K |
| A6197 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | <1% | 229 | $1K |
| 93970 | <1% | 44 | $1K | |
| G0378 | Hospital observation service, per hour | <1% | 1,316 | $1K |
| 82330 | <1% | 67 | $1K | |
| 73090 | <1% | 57 | $1K | |
| 80324 | <1% | 55 | $1K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 542 | $1K |
| 0225U | <1% | 175 | $990.83 | |
| 82800 | <1% | 92 | $967.94 | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 14 | $910.13 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,539 | $898.01 |
| 82248 | <1% | 184 | $893.84 | |
| 97003 | <1% | 29 | $889.92 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 40 | $817.40 |
| 74000 | <1% | 60 | $791.11 | |
| 78264 | <1% | 28 | $790.35 | |
| 85652 | <1% | 302 | $687.76 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,780 | $663.59 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 387 | $657.60 |
| 80346 | <1% | 28 | $601.20 | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 12 | $589.27 |
| 77065 | Tomosynthesis, mammo | <1% | 19 | $524.36 |
| 94010 | <1% | 13 | $521.71 | |
| 87807 | <1% | 40 | $494.38 | |
| 84100 | <1% | 143 | $442.58 | |
| 90686 | <1% | 54 | $432.72 | |
| A4364 | Adhesive, liquid or equal, any type, per oz | <1% | 43 | $429.29 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 2,550 | $395.86 |
| 94729 | <1% | 13 | $385.60 | |
| 83550 | <1% | 63 | $379.39 | |
| 83540 | <1% | 78 | $358.90 | |
| 36600 | <1% | 2,103 | $336.18 | |
| 93283 | <1% | 13 | $313.21 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 6,986 | $287.23 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,451 | $278.10 |
| 29581 | <1% | 103 | $267.01 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 167 | $256.35 |
| 72080 | <1% | 12 | $251.77 | |
| 81015 | <1% | 315 | $249.89 | |
| 74019 | <1% | 15 | $242.60 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,438 | $229.09 |
| 72170 | <1% | 17 | $208.84 | |
| 87340 | <1% | 41 | $206.50 | |
| 73140 | <1% | 15 | $194.42 | |
| 84295 | <1% | 44 | $192.36 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 42 | $190.00 |
| 82435 | <1% | 44 | $183.68 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 467 | $183.14 |
| 93242 | <1% | 15 | $180.21 | |
| 82570 | <1% | 30 | $175.63 | |
| 86308 | <1% | 18 | $137.26 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 402 | $133.94 |
| 84439 | <1% | 16 | $115.92 | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 16 | $88.50 |
| 83615 | <1% | 16 | $77.67 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 322 | $73.79 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 430 | $68.85 |
| 83986 | <1% | 13 | $62.82 | |
| 84156 | <1% | 24 | $60.95 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 13,364 | $49.95 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 41 | $48.60 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 188 | $41.27 |
| J2305 | Injection, nitroglycerin, 5 mg | <1% | 29 | $36.92 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 74 | $34.68 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 28 | $34.09 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 25 | $31.05 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 170 | $27.14 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,504 | $24.81 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 105 | $18.55 |
| J0737 | Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg | <1% | 13 | $16.31 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,851 | $15.84 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 111 | $15.67 |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 45 | $14.59 |
| 97116 | <1% | 526 | $11.47 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 81 | $9.75 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 103 | $2.38 |
| J0595 | Injection, butorphanol tartrate, 1 mg | <1% | 14 | $2.11 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,409 | $2.02 |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 48 | $1.29 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 103 | $0.60 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 377 | $0.52 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 456 | $0.32 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 137 | $0.19 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 137 | $0.19 |
| 96367 | 0% | 15 | $0.00 | |
| 92610 | 0% | 34 | $0.00 | |
| J3490 | Unclassified drugs | 0% | 381 | $0.00 |
| 36416 | 0% | 122 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 136 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 43 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 58 | $0.00 |
| J1805 | Injection, esmolol hydrochloride, 10 mg | 0% | 53 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 36 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWELLS, TROY (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Baptist Health Regional Hospitals | Fort Smith, AR | $17.49M |
| Baptist Health | Little Rock, AR | $16.48M |
| Baptist Health | Arkadelphia, AR | $4.82M |
| Conway Community Services | Conway, AR | $4.12M |
| Baptist Health | Heber Springs, AR | $3.69M |
| Baptist Health Hospitals | Stuttgart, AR | $2.97M |
| Baptist Health | Little Rock, AR | $2.93M |
| Baptist Health | Malvern, AR | $2.68M |
| Baptist Health Regional Hospitals | Van Buren, AR | $2.46M |
| Baptist Health | Little Rock, AR | $1.83M |
| Baptist Health | Arkadelphia, AR | $1.51M |
| Baptist Health Hospitals | Stuttgart, AR | $901K |
| Baptist Health | Little Rock, AR | $780K |
| Baptist Health | North Little Rock, AR | $411K |
| Baptist Health | Monticello, AR | $367K |
| Baptist Health | Conway, AR | $142K |
| Baptist Health | Little Rock, AR | $88K |
| Baptist Health | Prescott, AR | $33K |
| Baptist Health | Malvern, AR | $31K |
| Baptist Health | Heber Springs, AR | $22K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.